Lupus

Long-term exposure to air pollutants, including particulate matter, increases the risk for developing systemic lupus erythematosus, according to data published in Arthritis & Rheumatology.

ORLANDO, Fla. — Although rheumatic diseases must be considered in a differential diagnosis of autoimmune encephalitis, some patients can have both, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.

Infections account for most in-hospital mortality in childhood systemic lupus erythematosus, with patients exhibiting lupus nephritis or end-stage renal disease at increased risk, according to data published in The Journal of Rheumatology.

Metformin may protect against the progression of adverse renal and cardiovascular outcomes in patients systemic lupus erythematosus, including lupus nephritis and infarction, according to data published in ACR Open Rheumatology.

Specific interferon signatures may influence the symptoms and severity of systemic lupus erythematosus, with various interferon types potentially “contributing to distinct pathogenic processes,” according to recent findings.

Ongoing research into the disease processes of lupus has yielded an increased number of therapeutic targets, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.

Drugs used to treat diabetes and obesity, such as GLP-1 receptor agonists, are becoming an important treatment pathway in rheumatology, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.